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Abstract
Background: So far the prevalence of viral hepatitis infection in hospitalized patients has not been
extensively studied. Therefore we conducted the present five-year observational study to evaluate
the prevalence of HBV and HCV infection in high-risk hospitalized patients of Crete, the largest
Greek island, Due to the homogeneous population, epidemiological studies can be accurately done.
Methods: The study was carried out in two out of four District General Hospitals, and in the
University Hospital of the island. Markers for HBV and HCV were studied and statistically evaluated
according to age, sex and geographical area, in a well-defined hospitalized population.
Results: The total prevalence of HBsAg and anti-HCV in the three prefectures during the five-year
study is 2.66% and 4.75% respectively. Overall the relative risks were higher in males than females
for each hepatitis marker (p < 0.001). Higher prevalence of HBcAb was found in the 41–60 years
age group for both sexes (males 36.17%, females 27.38%). Peak HBsAg prevalence was found in the
age group of 21–40 and 41–60 years for males (5.4%) and females (3.09%) respectively. Anti-HCV
prevalence increases with age reaching the highest prevalence in the age group of 41–60 years for
males (7.19%) and in the 61–90 years age group for females (7.16%). For both sexes significant
differences between the three locations were identified. For HBsAg a higher prevalence in
Heraklion (3.96%) compared to Chania (2.30%, males: p < 0.0001, females: p < 0.05) and
Rethymnon (1.45%, males: p < 0.01, females: p < 0.0001) was detected. For HCV a significantly
higher prevalence in Heraklion (6.54%) compared to Chania (2.39%, males: p < 0.001, females: p <
0.001) but not in Rethymnon (5.15%, NS). A lower prevalence rate of HBcAb in Heraklion
compared to Chania (20.07% versus 23.05%, males: p < 0.001, females: p < 0.001) was found.
Conclusions: These results were possibly overestimated, but nevertheless reflect the situation of
the general population within the island as shown by our previous publications in other study
groups. Moreover they contribute to the mapping of viral hepatitis prevalence in a geographical
area of Southern Europe and may be helpful in planning public health interventional strategies.
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Background
The problem of viral hepatitis in hospital populations
around the world has not been adequately studied, al-
though hospitalized patients overall and especially certain
high risk groups among them, represent a possible source
for viral hepatitis infection of medical, nursing and auxil-
iary personnel caring for them as well as for their relatives
at home. Epidemiological studies concerning the preva-
lence of HBV and HCV markers in hospitalized patients
have been published, in isolated groups of high-risk pa-
tients [1–4] or hospital workers [5] worldwide.
Crete, the third largest island of the Mediterranean Sea,
has a very homogeneous population of 540.054 inhabit-
ants (1991 census). This allows for epidemiological stud-
ies to be conducted with accuracy. Clinical studies have
emphasized many differences between the island and
mainland Greece, in both liver cell carcinoma characteris-
tics and prevalence of viral markers [6]. A recent study in
blood donors in northwest Greece reported an HBsAg
prevalence of 0.85% [7] while a study of blood donors in
Crete has shown a significantly lower prevalence of 0.40%
for the same viral marker [8]. A survey of blood donors in
mainland Greece reported a 0.4% prevalence of anti-HCV
using a second generation enzyme linked immuno-assay
(ELISA 2) [9] not different from the overall prevalence
found with the same screening test in Crete (0.38%), but
with marked differences among the prefectures of the is-
land (Heraklion 0.52%, Rethymnon 0.52%, Chania
0.23%) [8].
Accepting that, high risk hospitalized patients are not the
ideal population for epidemiological studies, overestimat-
ing the problem, nonetheless they contribute in the epide-
miological mapping of a serious public health problem
like viral hepatitis, in a certain geographical area. The aim
of the present study was to investigate the prevalence of
hepatitis B and C markers in high-risk patients admitted
in two out of four District General Hospitals and in the
University Hospital of the island, during a five-year peri-
od, in an attempt to assess the situation in the hospitals of
the island.
Methods
We retrospectively analyzed the results of virological ex-
aminations for HBV and HCV, done on patients admitted
in the District General Hospitals of Chania and Rethym-
non and in the University Hospital of Heraklion during a
five-year period (1992–1996). All criteria for inclusion
and exclusion of a patient in the study had been agreed
upon, before starting the study in all three hospitals.
Chania and Rethymnon District General Hospitals serve
the total population of the corresponding two western
prefectures, while the University Hospital is the main hos-
pital, serving the two east prefectures of the island and it
is also the referral center of Crete for liver diseases.
Virological tests were done in the Department of Virology,
University Hospital and the Blood Banks of the other two
Hospitals. HBsAg and anti-HCV were studied in all three
hospitals while IgG-HBcAb was available only in Herak-
lion and Chania. Serum samples were tested by the micro-
particle capture enzyme immunoassay according to the
manufacturer's instructions, using kits from Abbott Labo-
ratories (North Chicago, IL); IMx HBsAg (hepatitis B sur-
face antigen), IMx CORE for IgG HBcAb and second and
third generation enzymed linked immunosorbent assays
(ELISA 2 and ELISA 3) for the detection of anti-HCV were
used.
281 184 admissions (138 850 males) were recorded in the
three hospitals during the study period of five years. Pa-
tients from day care hospital admissions were also includ-
ed. In all three hospitals patients were considered as high-
risk and included in the study if certain criteria applied
upon admission were met. The criteria for screening those
patients for hepatitis B and C were: Greek nationality, al-
coholism, altered liver function tests or exposure of the
patient to any risk factor;
Risk factors for HBV infection were: multiple sexual con-
tacts, family history, professional risk, major or minor sur-
gical or dental operations, iv drug abuse, tattooing or
piercing, previous transfusion, chronic renal failure under
dialysis and previous hospitalization over 5 days.
Risk factors for HCV infection were: homosexual contacts,
family history, professional risk, major or minor surgical
or dental operations, iv drug abuse, tattooing or piercing,
previous transfusion, previous hospitalization over 5 days
and chronic renal failure under dialysis.
Exclusion criteria for HBV testing was previous vaccina-
tion for hepatitis B with a recent proof of immunization.
A total of 46 901 patients (22 779 males) fulfilled the
above criteria and were tested for HBsAg. In 21 981 of
them (10 291 males), IgG-HBcAb was also studied. Anti-
HCV was tested in 34 155 patients (16 919 males). Dou-
ble tests were eliminated.
Statistical analysis
For the statistical analysis the relative risks (RR) were cal-
culated from the corresponding proportions. Simple bi-
nomial-based tests were used to test for differences in
proportions between the sexes at different time periods
and locations. Direct standardization was used in the
comparison of positivity rates at the three locations for
each of the sexes separately. Weighting was by the num-BMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/17
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bers investigated in each year under the assumption that
different subjects were tested each year. The standard pop-
ulation used, was the population calculated so that the
proportionate distribution was one third of the way be-
tween the three populations under study (Heraklion,
Rethymnon and Chania). The Rethymnon and Chania
populations were contrasted with the Heraklion popula-
tion using a version of Cochran s test [10]. The rates calcu-
lated in Cochran s test were drawn only from the two years
in which data were available for all three hospitals.
Results
The crude prevalence rates of the markers during the time
period considered are presented in Table 1.
Because of missing information in prevalence rates near
the start of the study, information has been lost for statis-
tical analysis. Data were not available yearly for Heraklion
early in the study-period; therefore the rates calculated in
Cochran s test, were drawn only from the two last years.
On the other hand, because of these drawbacks in analy-
sis, the extremely high and unexplained Rethymnon rates
for anti-HCV, which were registered in 1992, were not in-
cluded in the comparison between the three locations.
However, certain conclusions can be drawn.
Comparison between sexes and age groups
HBsAg
The proportion of males positive was overall significantly
higher, than that of females in all three hospitals. Relative
risks were 88%, >100% and 62% higher for males versus
females in Heraklion, Rethymnon and Chania respective-
ly, (p < 0.001 for the test of differences in prevalence rates
between males and females at each location). Considering
each time period separately, there was no year in which
the relative risk was significantly lower for males.
The prevalence of HBsAg in high-risk hospitalized pa-
tients of Crete, according to gender and age is shown in
figure 1. The higher prevalence for males 5.4%, was de-
tected in the 21–40 years age group, whether for females
the peak HBsAg carrier rate (3.09%) was detected in the
41–60 years age group. The lower prevalence rate of HB-
sAg infection (1.1%) was found at the age group of 0–20
years for both sexes. This might be due to the fact that in
Greece under the Guidelines of the Hellenic Society of
Pediatricians, the HBV vaccination program of neonates
has been going on since 1992, although it is only one year
that this program became obligatory. It is therefore ex-
pected that the HBV infection rate in young people will
further decline in the future.
HBcAb
the overall relative risks were 73% and 31% higher for
males than females in Heraklion and Chania respectively
(again p < 0.001 in both Heraklion and Chania). The
prevalence of HBcAb in high-risk hospitalized patients of
Heraklion and Chania, according to gender and age is
shown in figure 2. The peak exposure rates for both males
(36.17%) and females (27.38%) detected in the 41–60
years age groups are much higher than the ones reported
for blood donors (between 8% and 9.5% in different pre-
fectures) and probably are due to the fact that in general,
blood donors are younger than hospitalized patients.
When blood donors of over 40 years of age are consid-
ered, the exposure rates are similar (23.32%) [8].
anti-HCV
there were no overall differences between sexes in
Rethymnon, but in Heraklion and Chania the relative
risks were 23% and 39% higher for males as compared to
females (p < 0.001 and p < 0.01 respectively).
The prevalence of anti-HCV in high-risk hospitalized pa-
tients of Crete, according to gender and age is shown in
Figure 1
Prevalence (%) of HBsAg in male and female high-risk hospi-
talized patients of Crete according to age.
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Table 1: Prevalence rates (%) and relative risks (RR) of HBsAg, HBcAb and HCV in hospitalized patients over the 1992–1996 time period 
by sex.
Marker Location Year Males (m) tested % Females (f) tested % % (m+f) RR (m vs f)
HBsAg Heraklion 1992–4 2979 6,11 3553 2,81 4,32 2,17 **
1995 1874 4,59 2534 2,57 3,43 1,79 **
1996 1741 5,11 2710 3,25 3,98 1,57 *
Overall 5,41 2,88 3,96 1,88 **
Hania 1992 1502 3,13 1381 1,38 2,29 2,27 *
1993 3016 2,39 2634 1,29 1,88 1,85 *
1994 2782 3,16 2497 1,88 2,56 1,68 *
1995 2156 2,41 1710 2,11 2,28 1,15
1996 1847 3,14 1760 2,10 2,63 1,49
Overall 2,80 1,73 2,30 1,62 **
Rethymnon 1992 697 3,01 915 0,77 1,74 3,94 *
1993 1369 1,39 912 0,66 1,10 2,11
1994 871 2,41 1154 1,21 1,73 1,99
1995 970 1,75 1115 0,81 1,25 2,17
1996 975 2,15 1247 1,12 1,58 1,92
Overall 2,03 0,94 1,45 2,17 **
HBcAbn Heraklion 1992–4 2979 25.26 3553 17.69 21,14
1995 1874 24,76 2534 14,56 18,90 1,70 **
1996 1741 26,77 2710 15,09 19,66 1,77 **
Overall 25.51 15.99 20,07 1,73 **
Hania 1992 843 23,61 587 22,66 23,22 1,04
1993 919 22,63 712 24,16 23,30 0,94
1994 590 23,39 710 11,41 16,85 2,05 **
1995 816 34,80 424 28,30 32,58 1,23
1996 529 23,06 460 13,48 18,60 1,71 **
Overall 25,72 19,63 23,05 1,31 **
HCV Heraklion 1992–4 3319 8,44 3959 7,35 7,85 1,15
1995 1817 6,27 2361 5,12 5,62 1,22
1996 1713 6,25 2656 4,63 5,26 1,35
Overall 7,31 5,96 6,54 6,55 **
Hania 1992 739 1,49 903 0,78 1,10 1,92
1993 1323 2,34 901 2,11 2,25 1,11
1994 1928 4,15 1540 3,05 3,66 1,36
1995 1542 1,82 1075 2,23 1,99 0,81
1996 1794 2,79 1215 1,15 2,13 2,42 **
Overall 2,73 1,97 2,39 1,39 *
Rethymnon 1992 237 16,03 250 10,00 12,94 1,60
1993 763 3,93 452 7,52 5,27 0,52
1994 576 4,34 499 6,21 5,21 0,70
1995 573 2,27 618 3,72 3,02 0,61
1996 595 3,87 807 4,34 4,14 0,89
Overall 4,70 5,64 5,15 0,83
*Difference between sexes in the prevalence of the marker is significant at the 1% level, ** Difference between sexes in the prevalence of the marker 
is significant at the 0.1% level, nNot measured in RethymnonBMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/17
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figure 3. In accordance with our previous report on the
general population [11] anti-HCV prevalence increases
with age reaching the higher prevalence for males (7.19%)
in the age group of 41–60 years and for females (7,16%)
in the 61–90 years age group.
Comparison between the locations
For both sexes there was evidence of significant differenc-
es between the three locations, this evidence being more
apparent in males than females (Table 1). More specifical-
ly, for both sexes, evidence was provided by Cochran s
test, of significant differences in the three viral markers.
HBsAg
Higher prevalence in Heraklion (3.96%) than Chania
(2.30%) (males: p < 0.0001, females: p < 0.05), and
Rethymnon (1.45%) (males: p < 0.01, females: p <
0.0001).
anti-HCV
Higher prevalence in Heraklion (6.54%) than Chania
(2.39%) (males: p < 0.001, females: p < 0.001), but no
significant difference between Heraklion and Rethymnon
(5.15%) in males or females. It is interesting to note that,
the Rethymnon prefecture with the lowest percentage of
HBsAg, has a high prevalence of anti-HCV. A similar situ-
ation has been reported in volunteer blood donors on the
island, where in the same prefecture with the lowest rate
of HBsAg (0.27%) the highest rate of anti-HCV (0.52%)
was found [8]. Moreover pockets of very high prevalence
of anti-HCV have been discovered in the Rethymnon area
[11]. These results are also in accordance with the higher
prevalence of hepatocellular carcinoma due to HCV in the
Rethymnon area [6].
HBcAb
Lower prevalence in Heraklion (20.07%) than Chania
(23.05%) (males: p < 0.001, females: p < 0.001). For sim-
ilar exposure rates to HBV, there was a significant decrease
Figure 2
Prevalence (%) of HBcAb in male and female high-risk hospi-
talized patients of Heraklion and Chania according to age.
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Figure 3
Prevalence (%) of anti-HCV in male and female high-risk hos-
pitalized patients of Crete according to age.
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in carrier rate in Chania. This was true for practically every
year and for both sexes. It was very clear in the year of
1995, when although the exposure rates were 32.58% in
Chania versus 18.90% in Heraklion, carrier rates were
2.28% versus 3.43% respectively. Even on similar expo-
sure rates, as during 1996, (Chania: 18.6% versus Herak-
lion: 19.66%) fewer people became carriers in Chania
than in Heraklion (2.63% versus 3.96%). Since the popu-
lation of these two prefectures is genetically homogene-
ous and the age groups of hospitalized patients were
similar we suspect that the lower carrier rate in Chania
might be related to an, as yet unidentified environmental
factor.
In general the RR were higher in males for each hepatitis
marker. This observation agrees with the earlier report in
blood donors [8]. When results are analyzed according to
sex and location, the male predominance is universal with
one notable exception for anti-HCV in Rethymnon, which
we call the Rethymnon female paradox. Females in
Rethymnon have a higher HCV infection rate than males,
a feature unique in the island, which we already reported
in a study of general population in a rural area of Rethym-
non (males: 2.4%, females: 3.7%) [11], and in the study
of the volunteer blood donors (males: 0.37%, females:
0.49%) [8]. The reason for this discrepancy is not clear. In-
travenous drugs cannot be the explanation since the same
phenomenon appeared in an isolated community where
no drugs exist [11]. Moreover, almost 90% of our HCV
cases are of the sporadic type with no obvious source of
infection. Medical and particularly midwifery malpractice
of the recent past in the Rethymnon area, appears to be a
rational explanation.
The University hospital of Heraklion is a referral center,
with a much larger catchment area than the regional hos-
pitals of Rethymnon and Chania that could be directly
compared. Therefore the last two were compared in crude
prevalence rates of the markers over the five-year period
for males and females separately, using the binomial test
for proportions. As can be seen in Table 2, for both the
male and female populations, evidence was provided of a
significantly:
• Lower prevalence in Rethymnon than Chania for HBsAg
(p < 0.001 and p < 0.0001 for males and females respec-
tively).
• Higher prevalence of anti-HCV in Rethymnon than Cha-
nia (p < 0.0001 for both males and females).
The prevalence of HBV and HCV markers of patients, in
the English publications during the past 10 years refers to
isolated high-risk groups. Thus, a published survey of
HBV and HCV infection markers from a referral center of
Northern Greece among alcoholics with chronic liver dis-
ease, alcoholics without chronic liver disease, hospital-
ized non-alcoholic patients and healthy controls, reported
an HBsAg prevalence rate of 10.8%, 7.4%, 1.4% and
2.1%, an HBcAb prevalence rate of 39.2%, 36.4%, 14.3%
and 19.5% and an anti-HCV prevalence rate of 1.2%,
1.4% 0% and 0.6% respectively [12]. The prevalence rates
of HBV viral markers in the non-alcoholic hospitalized
patients are lower than ours while our figures come closer
to the ones reported in their healthy control group. Fur-
thermore our anti-HCV prevalence rates exceed theirs. The
small number of patients included in the hospitalized
non-alcoholic patients (70 patients) may be a problem for
a direct comparison of the two studies but still we believe
that these differences do reflect the different situation be-
tween Crete and mainland Greece. In another Greek
study, the prevalence of anti-HCV of patients in haemodi-
alysis was found to be 17.6% [13] while Romanian pa-
tients on dialysis since 1996 have an anti-HCV prevalence
of 28.6% and an HBsAg prevalence of 21.6% [2]. High
prevalence rates for HBsAg (15.3%) and anti-HCV (9.7%)
were reported among non-intravenous-drug-using pa-
tients [1] attending clinics for sexually transmitted diseas-
es that probably underline the importance of the sexual
transmission of the viruses [14]. A recent report of Greek
HIV-positive patients, reported prevalence rates of HBV
extremely elevated at 67.4% rising to 90.9% in the blood
Table 2: A comparison of crude prevalence rates (%) for the markers HBsAg and anti-HCV in Rethymnon and Hania over the 1992–6 
period.
Rethymnon % Hania % Difference in prevalence 95%CI
Males HBsAg 2.03 2.80 -0.008 (-0.013, -0.003)*
anti-HCV 4.70 2.73 0.020 (0.011, 0.028)**
Females HBsAg 0.94 1.73 -0.008 (-0.012, 0.004)**
Anti-HCV 5.64 1.97 0.037 (0.027, 0.046)**
*p < 0.001, **p < 0.0001, CI : Confidence IntervalBMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/17
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transfusion recipients, while anti-HCV were 13.8% rising
to 45.5% in blood transfusion recipients [15]. Similarly in
Italy HIV-positive patients have HBV infection markers
prevalence rate of 82% and anti-HCV prevalence rate of
72% if they are drug addicts while the prevalence rate is
77% for HBV markers and 7% for anti-HCV if HIV-posi-
tive patients are homosexuals [4]. These extremely elevat-
ed figures apply to an even more selected high risk-group
of patients, compared to our study. In a survey from main-
land Greece HCV infection was responsible for 25% of
chronic liver disease patients [16]. Higher figures than
ours (18% anti-HCV, and 5% HBsAg) have been pub-
lished concerning patients in an inner-city emergency de-
partment in a study that lasted for only six weeks [3].
It is obvious that due to the lack of homogeneity of the
study groups mentioned before, direct comparisons of the
present study with reports either from Greece or from oth-
er parts of the world may be illusive.
Conclusions
In the present study we investigated the prevalence rates of
HBV and HCV markers in high-risk hospitalized patients
of Crete in a study period of five years. We consider im-
portant that similar studies are extended over a period of
many years, since infection rates are not similar each year
and a limited study period will not yield representative re-
sults. HBsAg had an overall prevalence rate of 2.66% with
a significant difference between sexes (3.39% males,
1.97% females). A lower carrier rate was detected under
the age of 20 years and peak carrier rates in middle age
groups. HBcAb results showed an overall exposure rate to
HBV virus of 20.96%, with the higher exposure rate for
both sexes detected in the 41–60 years age group. anti-
HCV had an overall prevalence rate of 4.75% with no sig-
nificant differences between sexes (males: 4.90%, females:
4.60%), increasing with age and peaking in the 41–60
years age group for males and in the 61–90 years age
group for females. This finding confirms our previous
field studies reporting high anti-HCV prevalence (4.8%)
in outpatients of primary health care centers in Crete [17].
In conclusion, we believe that, viral hepatitis markers
prevalence rates of the high-risk hospitalized patients in
Crete, overestimate but reflect the situation in the general
population of the island. Our results also underline the
differences between the island and mainland Greece,
which is a country of intermediate prevalence of HBV and
HCV infection. Additionally these data contribute to the
mapping of viral hepatitis prevalence in this geographical
area of Southern Europe and therefore may be helpful in
planning public health interventional strategies.
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